Clinical perspective, offered as context rather than as advice.
Vendor communication red flags for compounded supply:
- Won't provide COA before purchase — walk away
- Claims "100% pure" without analytical data — unrealistic
- No physical address or phone number — accountability matters
- Pushes you to buy more than you need — pressure tactics
- Won't answer questions about their compounding process — transparency is key
- Payment only via crypto or wire transfer — legitimate pharmacies accept cards
A legitimate compounding pharmacy operates like a healthcare business, not a gray market dealer.
TirzTom said:GMP compliance checklist relevant to compounded supply compounding quality: Clean room environment with HEPA filtration Environmental monitoring…
Price comparison for compounded supply across sources I've used:
| Source | Monthly Cost | Type | Purity Verified |
|---|---|---|---|
| Brand (Ozempic) | $1066 | FDA-approved | N/A (pharma) |
| 503B Compounding | $146 | cGMP compounded | Yes (in-house) |
| 503A Compounding | $96 | Patient-specific | Varies |
| Research peptide | $56 | Not for human use | Often Janoshik |
I use the 503B option — best balance of quality, cost, and legality. The brand price is insane but insurance can help if you qualify.
A narrower follow-up, since the general answer is now clear:
How would you tell the difference between that and the alternative explanation?
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference Standardsdan_philly said:Price comparison for compounded supply across sources I've used: Source Monthly Cost Type Purity Verified Brand (Ozempic) $1066 FDA-approved N/A…
Regarding compounded supply compounding legality: compounding pharmacies can legally produce semaglutide and tirzepatide while these drugs remain on the FDA shortage list. If/when the shortage resolves, the legal landscape may change.
Stay informed. The FDA shortage list is updated regularly. Current status as of my last check: semaglutide partially resolved shortage, tirzepatide still in shortage. This directly impacts compounding availability.